secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-076530
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon reports 2025 net loss of $345.9M; Phase 3 X-TOLE2 data expected in March 2026
--------------------------------------------------------------------------------

- Net loss $345.9M in 2025 vs $234.3M in 2024; R&D expense rose to $300.9M on azetukalner Phase 3 trials.
- Pro forma cash $716M (incl. $130M ATM in Q1 2026) extends runway into H2 2027.
- Phase 3 X-TOLE2 topline data for azetukalner in focal onset seizures due first half of March 2026.
- NDA submission for azetukalner in FOS planned H2 2026; 5 additional Phase 3 studies in epilepsy and depression enrolling.
- Early-stage pipeline: Phase 1 data for XEN1701 (NaV1.7) and XEN1120 (KV7) pain candidates expected in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000119312526076530/0001193125-26-076530-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000119312526076530/xene-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-076530

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer